Chordia Therapeutics Inc. (JP:190A) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chordia Therapeutics Inc. has released the transcript of its earnings briefing for the fiscal year ended August 2024, aiming to enhance transparency and investor understanding. The company is actively developing cancer therapies, with its lead candidate CTX-712 undergoing Phase 1/2 clinical trials in the US.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.